{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:10:24Z","timestamp":1790212224608,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007287","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jconrel.2026.115275","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:23:55Z","timestamp":1787495035000},"page":"115275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Nanoparticles-mediated dual drug administration boosts therapeutic efficacy in drug resistant melanoma"],"prefix":"10.1016","volume":"398","author":[{"given":"Giulia","family":"Lovati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Milesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica Maria","family":"Prandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodovico","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Mileti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Doni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Tiboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Casettari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Beccalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Jodice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Barberis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Francesco","family":"Benvenuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sigismund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Marocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Lanfrancone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Baldelli Bombelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.115275_bb0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41572-025-00603-8","article-title":"Cutaneous melanoma","volume":"11","author":"Tasdogan","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jconrel.2026.115275_bb0010","first-page":"79","article-title":"Melanoma - modern treatment for metastatic melanoma","volume":"30","author":"Dimitrova","year":"2024","journal-title":"Cancer J. (United States)"},{"key":"10.1016\/j.jconrel.2026.115275_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104276","article-title":"The treatment of advanced melanoma: current approaches and new challenges","volume":"196","author":"Boutros","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.jconrel.2026.115275_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1504142","article-title":"The evolution of BRAF-targeted therapies in melanoma: overcoming hurdles and unleashing novel strategies","volume":"14","author":"Imani","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.115275_bb0025","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.det.2025.03.004","article-title":"Systemic therapies for metastatic melanoma","volume":"43","author":"Latoni","year":"2025","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.jconrel.2026.115275_bb0030","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3390\/cancers16081571","article-title":"Current state of melanoma therapy and next steps: battling therapeutic resistance","volume":"16","author":"Fateeva","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.115275_bb0035","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/14737140.2025.2474182","article-title":"Melanoma neoadjuvant treatment: review and update of recent trials","volume":"25","author":"Ferrari","year":"2025","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.jconrel.2026.115275_bb0040","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbcan.2019.02.002","article-title":"Many ways to resistance: how melanoma cells evade targeted therapies","volume":"1871","author":"Kozar","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115275_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2016.00033","article-title":"The complexity of the ERK\/MAP-kinase pathway and the treatment of melanoma skin cancer","volume":"4","author":"Wellbrock","year":"2016","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115275_bb0050","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","article-title":"Signal pathways of melanoma and targeted therapy","volume":"6","author":"Guo","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115275_bb0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-019-1847-2","article-title":"Metabolic heterogeneity confers differences in melanoma metastatic potential","volume":"577","author":"Tasdogan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115275_bb0060","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fonc.2018.00173","article-title":"Microenvironment-driven dynamic heterogeneity and phenotypic plasticity as a mechanism of melanoma therapy resistance","volume":"8","author":"Ahmed","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2026.115275_bb0065","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/genes14051021","article-title":"The genomic landscape of melanoma and its therapeutic implications","volume":"14","author":"Yang","year":"2023","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jconrel.2026.115275_bb0070","doi-asserted-by":"crossref","first-page":"16110","DOI":"10.18632\/oncotarget.24576","article-title":"Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer","volume":"9","author":"Noeparast","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2026.115275_bb0075","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1158\/1078-0432.CCR-14-1554","article-title":"BRAF inhibition stimulates melanoma-associated macrophages to drive tumor growth","volume":"21","author":"Wang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115275_bb0080","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/2159-8290.CD-13-1007","article-title":"The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNF","volume":"4","author":"Smith","year":"2014","journal-title":"Cancer Discov."},{"issue":"7408","key":"10.1016\/j.jconrel.2026.115275_bb0085","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2026.115275_bb0090","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.3390\/cancers12113400","article-title":"A framework of major tumor-promoting signal transduction pathways implicated in melanoma-fibroblast dialogue","volume":"12","author":"Bellei","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115275_bb0095","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","article-title":"Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer","volume":"6","author":"Wu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7974","key":"10.1016\/j.jconrel.2026.115275_bb0100","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41586-023-06342-8","article-title":"Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells","volume":"620","author":"Goyal","year":"2023","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.jconrel.2026.115275_bb0105","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41389-018-0081-3","article-title":"Oncogenic PI3K\/AKT promotes the step-wise evolution of combination BRAF\/MEK inhibitor resistance in melanoma","volume":"7","author":"Irvine","year":"2018","journal-title":"Oncogenesis"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115275_bb0110","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115275_bb0115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1158\/0008-5472.CAN-06-1880","article-title":"Tumor necrosis factor-\u03b1 blocks apoptosis in melanoma cells when BRAF signaling is inhibited","volume":"67","author":"Gray-Schopfer","year":"2007","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115275_bb0120","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nm.4369","article-title":"An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer","volume":"23","author":"Xue","year":"2017","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115275_bb0125","first-page":"964","article-title":"Determinants of resistance and response to melanoma therapy","volume":"5","author":"Robertson","year":"2024","journal-title":"Nat. Can."},{"key":"10.1016\/j.jconrel.2026.115275_bb0130","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with braf v600-mutant metastatic melanoma receiving dabrafenib combined with trametinib","volume":"34","author":"Long","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2026.115275_bb0135","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_404770","article-title":"Expanding the benefit: dabrafenib\/trametinib as tissue-agnostic therapy for BRAF V600E\u2013positive adult and pediatric solid tumors","author":"Gouda","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.jconrel.2026.115275_bb0140","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.115275_bb0145","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115275_bb0150","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB\u2013C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2026.115275_bb0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2026.115275_bb0160","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2026.115275_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.matdes.2020.108805","article-title":"Review of hybrid PLGA nanoparticles: future of smart drug delivery and theranostics medicine","author":"Ghitman","year":"2020","journal-title":"Mater. Des."},{"key":"10.1016\/j.jconrel.2026.115275_bb0170","series-title":"Skin Cancer Biology and Barriers to Treatment: Recent Applications of Polymeric Micro\/Nanostructures","author":"Khan","year":"2026"},{"key":"10.1016\/j.jconrel.2026.115275_bb0175","doi-asserted-by":"crossref","DOI":"10.1038\/s41596-023-00843-6","article-title":"Development of ionic liquid-coated PLGA nanoparticles for applications in intravenous drug delivery","volume":"18","author":"Hamadani","year":"2023","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.jconrel.2026.115275_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2023.100197","article-title":"Nanoparticles as a therapeutic delivery system for skin cancer prevention and treatment","volume":"3","author":"Chang","year":"2023","journal-title":"JID Innov."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115275_bb0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-022-01708-4","article-title":"Advancements in nanoparticle-based treatment approaches for skin cancer therapy","volume":"22","author":"Zeng","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115275_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25042165","article-title":"Nanotechnology as a promising method in the treatment of skin cancer","volume":"25","author":"Adamus-Grabicka","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115275_bb0195","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1039\/D0CS01127D","article-title":"Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine","volume":"50","author":"Sousa De Almeida","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2026.115275_bb0200","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2174\/1389201022666210714145356","article-title":"Cellular uptake pathways of nanoparticles: process of endocytosis and factors affecting their fate","volume":"23","author":"Varma","year":"2021","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.jconrel.2026.115275_bb0205","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41568-023-00574-6","article-title":"Endocytosis in cancer and cancer therapy","volume":"23","author":"Banushi","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2026.115275_bb0210","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/ijc.32662","article-title":"The fidelity of cancer cells in PDX models: characteristics, mechanism and clinical significance","volume":"146","author":"Shi","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2026.115275_bb0215","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12943-017-0745-1","article-title":"Generation of stable PDX derived cell lines using conditional reprogramming","volume":"16","author":"Borodovsky","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2026.115275_bb0220","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/2159-8290.CD-15-1200","article-title":"In vivo genetic screens of patient-derived tumors revealed unexpected frailty of the transformed phenotype","volume":"6","author":"Bossi","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2026.115275_bb0225","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1158\/1078-0432.CCR-15-1762","article-title":"Personalized preclinical trials in BRAF inhibitor-resistant patient-derived xenograft models identify second-line combination therapies","volume":"22","author":"Krepler","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2026.115275_bb0230","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jid.2023.03.1665","article-title":"Actionable genetic screens unveil targeting of AURKA, MEK, and fatty acid metabolism as an alternative therapeutic approach for advanced melanoma","volume":"143","author":"Marocchi","year":"2023","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jconrel.2026.115275_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120464","article-title":"Microfluidics for nanomedicines manufacturing: an affordable and low-cost 3D printing approach","volume":"599","author":"Tiboni","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115275_bb0240","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1038\/s41598-017-04125-6","article-title":"Development of lysosome-mimicking vesicles to study the effect of abnormal accumulation of sphingosine on membrane properties","volume":"7","author":"Carreira","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2026.115275_bb0245","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3892\/ijo.2016.3594","article-title":"Targeting the PI3K\/AKT\/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor","volume":"49","author":"Caporali","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.jconrel.2026.115275_bb0250","doi-asserted-by":"crossref","first-page":"113472","DOI":"10.18632\/oncotarget.23052","article-title":"Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib","volume":"8","author":"Caporali","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2026.115275_bb0255","doi-asserted-by":"crossref","DOI":"10.1172\/JCI165368","article-title":"GPR126 is a specifier of blood-brain barrier formation in the mouse central nervous system","volume":"134","author":"Kakogiannos","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2026.115275_bb0260","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinforma."},{"key":"10.1016\/j.jconrel.2026.115275_bb0265","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.jconrel.2026.115275_bb0270","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4997\/jrcpe.2021.412","article-title":"Pauci-immune crescentic glomerulonephritis associated with metastatic rectal carcinoma","volume":"51","author":"Swift","year":"2021","journal-title":"J. R. Coll. Physicians Edinb."},{"key":"10.1016\/j.jconrel.2026.115275_bb0275","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4638192","article-title":"The dual role of the liver in nanomedicine as an actor in the elimination of nanostructures or a therapeutic target","volume":"2020","author":"Baboci","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.jconrel.2026.115275_bb0280","article-title":"The dose threshold for nanoparticle tumour delivery","author":"Poon","year":"2026","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2026.115275_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00120","article-title":"Combined inhibition of MEK and Aurora a kinase in KRAS\/PIK3CA double-mutant colorectal cancer models","volume":"6","author":"Davis","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115275_bb0290","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1054\/bjoc.2001.1796","article-title":"Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials","volume":"84","author":"Johnson","year":"2001","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.jconrel.2026.115275_bb0295","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd.2016.175","article-title":"Screening out irrelevant cell-based models of disease","volume":"15","author":"Horvath","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7718","key":"10.1016\/j.jconrel.2026.115275_bb0300","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","article-title":"Genetic and transcriptional evolution alters cancer cell line drug response","volume":"560","author":"Ben-David","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115275_bb0305","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115275_bb0310","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","article-title":"Current advance of nanotechnology in diagnosis and treatment for malignant tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115275_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111559","article-title":"Reprogramming the melanoma and immunosuppressive myeloid cells with esomeprazole-loaded PLGA nanoparticles","volume":"28","author":"Cerioli","year":"2025","journal-title":"IScience"},{"key":"10.1016\/j.jconrel.2026.115275_bb0320","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1126\/sciadv.adr4762","article-title":"Two-in-one nanoparticle platform induces a strong therapeutic effect of targeted therapies in P-selectin-expressing cancers","volume":"10","author":"Koshrovski-Michael","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2026.115275_bb0325","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1039\/D0CS01127D","article-title":"Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine","volume":"50","author":"Sousa De Almeida","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115275_bb0330","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41565-021-00858-8","article-title":"Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics","volume":"16","author":"Rennick","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2026.115275_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.crimmu.2023.100073","article-title":"Nanoparticles cellular uptake, trafficking, activation, toxicity and in vitro evaluation","volume":"4","author":"Toscano","year":"2023","journal-title":"Curr. Res. Immunol."},{"key":"10.1016\/j.jconrel.2026.115275_bb0340","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1039\/C7NR00532F","article-title":"Systematic investigation on the intracellular trafficking network of polymeric nanoparticles","volume":"9","author":"Zhang","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2026.115275_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114480","article-title":"Transcytosis-enabled active extravasation of tumor nanomedicine","volume":"189","author":"Zhou","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115275_bb0350","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41563-020-0672-1","article-title":"Active transcytosis and new opportunities for cancer nanomedicine","volume":"19","author":"Pandit","year":"2020","journal-title":"Nat. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115275_bb0355","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1038\/s41467-025-61434-5","article-title":"Unlocking tumor barrier: annexin A2-mediated transcytosis boosts drug delivery in pancreatic and breast tumors","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2026.115275_bb0360","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202300125","article-title":"Stimuli-responsive nanocarriers for transcytosis-based cancer drug delivery","volume":"4","author":"Wang","year":"2024","journal-title":"Adv. Nanobiomed. Res."},{"key":"10.1016\/j.jconrel.2026.115275_bb0365","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","article-title":"The entry of nanoparticles into solid tumours","volume":"19","author":"Sindhwani","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2026.115275_bb0370","article-title":"Better together: nanoscale co-delivery systems of therapeutic agents for high-performance cancer therapy","volume":"15","author":"Sun","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115275_bb0375","first-page":"9","article-title":"Multifunctional nanoparticle-mediated combining therapy for human diseases","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2026.115275_bb0380","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1080\/10717544.2017.1410256","article-title":"Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy","volume":"24","author":"Qi","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115275_bb0385","doi-asserted-by":"crossref","first-page":"894","DOI":"10.7150\/thno.21168","article-title":"Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development","volume":"8","author":"Sung","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2026.115275_bb0390","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3390\/pharmaceutics16080981","article-title":"Local, sustained, and targeted co-delivery of MEK inhibitor and doxorubicin inhibits tumor progression in E-cadherin-positive breast cancer","volume":"16","author":"Kuhn","year":"2024","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115275_bb0395","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1007\/s13346-021-01065-7","article-title":"The MEK 1\/2 inhibitor PD98059 exhibits synergistic anti-endometrial cancer activity with paclitaxel in vitro and enhanced tissue distribution in vivo when formulated into PAMAM-coated PLGA-PEG nanoparticles","volume":"12","author":"Wiwatchaitawee","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.115275_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2025.114795","article-title":"Research progress of co-delivery nanoparticle drug delivery systems in non-small cell lung cancer: a review","volume":"254","author":"Wu","year":"2025","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.jconrel.2026.115275_bb0405","doi-asserted-by":"crossref","first-page":"8281","DOI":"10.1016\/j.biomaterials.2011.07.032","article-title":"Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles","volume":"32","author":"Wang","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2026.115275_bb0410","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijpharm.2017.03.087","article-title":"Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles","volume":"525","author":"Labala","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2026.115275_bb0415","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/ijms18071527","article-title":"Role played by signalling pathways in overcoming BRAF inhibitor resistance in melanoma","volume":"18","author":"Chan","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115275_bb0420","doi-asserted-by":"crossref","first-page":"237","DOI":"10.21037\/atm.2016.06.07","article-title":"Resistant mechanisms to BRAF inhibitors in melanoma","volume":"4","author":"Manzano","year":"2016","journal-title":"Ann. Transl. Med."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926006796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926006796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:58:43Z","timestamp":1790211523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926006796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":84,"alternative-id":["S0168365926006796"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115275","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoparticles-mediated dual drug administration boosts therapeutic efficacy in drug resistant melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115275"}}